Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R2 (IIIb)

FGF R2 (IIIb)

Brief Information

Name:Fibroblast growth factor receptor 2
Target Synonym:EC:2.7.10.1,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC 2.7.10.1,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Number of Launched Drugs:9
Number of Drugs in Clinical Trials:29
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

FGB-H5223-SPR
 FGF R2 (IIIb) SPR

Biotinylated Human FGF-10, His,Avitag (Cat. No. FG0-H81Q7) immobilized on SA Chip can bind Human FGFR2 (IIIb), His Tag (Cat. No. FGB-H5223) with an affinity constant of 5.02 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

FGB-M52H5-ELISA
 FGF R2 (IIIb) ELISA

Immobilized Mouse FGFR2 (IIIb), His Tag (Cat. No. FGB-M52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Avitag,His Tag (Cat. No. FGC-H81E3) with a linear range of 0.039-1.25 μg/mL (QC tested).

Synonym Name

FGF R2 (IIIb),FGFR2B,FGFR2

Background

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Carcinoma, Non-Small-Cell Lung Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Thyroid Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Medullary thyroid cancer (MTC); Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Thyroid Neoplasms Eisai Inc 2015-02-13 Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Colorectal Neoplasms Bayer Healthcare Pharmaceuticals Inc 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef United States Idiopathic Pulmonary Fibrosis Boehringer Ingelheim Gmbh 2014-10-15 Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors Details
Futibatinib TAS-120 Approved Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd LYTGOBI United States Cholangiocarcinoma Taiho Oncology Inc 2022-09-30 Central Nervous System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Lymphoma; Metastatic breast cancer; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; Bone Marrow Neoplasms; Solid tumours Details
Selpercatinib ARRY-192; Ret-IN-1; LOXO-292; LY-3527723 Approved Array Biopharma Retevmo, Retsevmo United States Medullary thyroid cancer (MTC); Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms Loxo Oncology Inc 2020-05-08 Medullary thyroid cancer (MTC); Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Hepatic Insufficiency; Neuroblastoma; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing; Osteosarcoma; Fibrosarcoma; Sarcoma; Myofibromatosis; Wilms Tumor; Neoplasms; Thyroid Carcinoma, Anaplastic; Colonic Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Renal Insufficiency; Medulloblastoma; Ependymoma; Rhabdomyosarcoma; Hematologic Neoplasms; Solid tumours Details
Pemigatinib INCB-054828; INCB-54828; IBI-375 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 United States Cholangiocarcinoma Incyte Corp 2020-04-17 Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Lymphoma, Non-Hodgkin; Glioma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Urologic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Colitis, Ulcerative; Translocation, Genetic; Breast Neoplasms; Biliary Tract Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Solid tumours; Bone Marrow Neoplasms Details
Tasurgratinib E-7090 Approved Eisai Co Ltd TASFYGO Japan Biliary Tract Neoplasms Eisai Co Ltd 2024-09-24 Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
Erdafitinib 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 Approved Astex Pharmaceuticals Inc Balversa, 博珂 United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Carcinoma, Squamous Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma; Glioma; Metastatic breast cancer; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Adenocarcinoma; Hepatoblastoma; Ependymoma; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Bone metastases; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Rhabdoid Tumor; Solid tumours; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Wilms Tumor; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Prostatic Neoplasms, Castration-Resistant; Histiocytosis, Langerhans-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Bemarituzumab FPA-144 Phase 3 Clinical Five Prime Therapeutics Inc Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
Rogaratinib BAY-1163877 Phase 3 Clinical Bayer AG Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
Infigratinib BGJ-398; NVP-BGJ398 Phase 3 Clinical Novartis Pharma Ag Pancreatic Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Gastrointestinal Stromal Tumors; Oropharyngeal Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Biliary Tract Neoplasms; Glioblastoma; Achondroplasia; Papillomavirus Infections; Neoplasms; Nasopharyngeal Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours Details
SC-0011 SC-0011 Phase 3 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Zoligratinib CH-5183284; FF-284; Debio-1347 Phase 2 Clinical Chugai Pharmaceutical Co Ltd Solid tumours; Breast Neoplasms Details
AUR-109 ODM-203; AUR-109 Phase 2 Clinical Orion Corp Ovarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms Details
Lucitanib S-80881; AL-3810; CO-3810; E-3810; S-80881-2 Phase 2 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Fexagratinib AZD4547; AZD-4547; ABSK-091; ABSK091 Phase 2 Clinical Astrazeneca Plc Lymphoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Glioma; Uterine Neoplasms; Urinary Bladder Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details
HH185 3D-185; 3-D185; HH-185; 3D185 Phase 2 Clinical ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc Solid tumours; Cholangiocarcinoma Details
3HP-2827 3HP-2827; 3HP2827 Phase 2 Clinical 3H (Suzhou) Pharmaceuticals Co Ltd Solid tumours; Neoplasms Details
CGT-4859 CGT4859; CGT-4859 Phase 2 Clinical Cogent Biosciences Inc Solid tumours; Neoplasms; Cholangiocarcinoma Details
HMPL-453 HMPL-453 Phase 2 Clinical Hutchison Medipharma Ltd Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma Details
ABSK-061 ABSK061 Phase 2 Clinical ABbisko Therapeutics Co Ltd Solid tumours; Esophageal Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung Details
Lirafugratinib RLY-4008 Phase 2 Clinical Relay Therapeutics Inc Solid tumours; Translocation, Genetic; Cholangiocarcinoma Details
PZH-2111 PZH2111; PZH-2111 Phase 2 Clinical Zhangzhou Pientzehuang Pharmaceutical Co Ltd Solid tumours; Cholangiocarcinoma Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
nintedanib (Avalyn Pharma) Phase 1 Clinical Avalyn Pharma Inc Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis Details
TYRA-200 TYRA200; TYRA-200 Phase 1 Clinical Tyra Biosciences Inc Solid tumours; Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms Details
Resigratinib KIN-3248; KIN-003 Phase 1 Clinical Kinnate Biopharma Inc Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Cholangiocarcinoma Details
BG-C137 BG-C137 Phase 1 Clinical BeOne Medicines Ltd Solid tumours; Gastrointestinal Neoplasms Details
ACE-16229210 ACE-16229210; ACE16229210 Phase 1 Clinical Acerand Therapeutics (Shanghai) Ltd Solid tumours Details
MNKD-201 MNKD-201; MKND-201 Phase 1 Clinical MannKind Corp Idiopathic Pulmonary Fibrosis Details
Inhaled Nintedanib – dry powder (Avalyn Pharma) AP02; AP 02 DP; AP-02; AP02-DP Phase 1 Clinical Avalyn Pharma Inc Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis Details
TT-00434 TT-00434 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours; Urinary Bladder Neoplasms Details
ABSK-121 ABSK121-NX; ABSK121 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
LY-2874455 LY-2874455 Phase 1 Clinical Eli Lilly And Company Neoplasms; Leukemia, Myeloid, Acute Details
CPL-304110 CPL-304110; CPL-304-110 Phase 1 Clinical Celon Pharma Sa Stomach Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Sarcoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message